medigraphic.com
ISSN 1561-302X (Print)

2019, Number 2

<< Back Next >>

Rev cubana med 2019; 58 (2)

The end of aspirin in primary prevention of cardiovascular diseases

Arredondo BA

Language: Spanish
References: 19
Page: 1-10
PDF size: 237.11 Kb.


ABSTRACT

Introduction: Aspirin is currently the most widely used drug worldwide. During 2018, at least partially, the risk/benefit ratio of aspirin in primary prevention was questioned.
Objective: To update the true risk/benefit value of aspirin in the primary prevention of cardiovascular diseases.
Methods: A review of the papers published in the last five years, on the use of aspirin in the primary prevention of cardiovascular diseases, was carried out. Twenty publications were selected in Medline, Embase, and SciELO.
Discussion: There are important, high-quality, randomized, independent studies that have questioned the quality of aspirin in primary prevention.
Results: The first results of the THEMIS study will contribute to understanding the future role of antiplatelet agents in primary prevention as to avoid the consequences of atherosclerotic plaque rupture in patients with the possibility of suffering from asymptomatic atherosclerotic plaque rupture.
Conclusions: The advantages of the use of aspirin as a primary prophylaxis of cardiovascular disease are ruled out, due to the frequent appearance of sometimes serious bleeding; however, aspirin continues to be proposed as a very useful medicine in secondary prophylaxis, in addition to promoting the use of statins.


REFERENCES

  1. Braña MF, del Río LA, Trives C, Salazar N. La verdadera historia de la Aspirina. In Anales de la Real Academia Nacional de Farmacia. 2015[acceso: 14/01/2019];71(4). Disponible en: http://analesranf.com/index.php/aranf/article/view/215

  2. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018[acceso: 14/01/2019];392:1036-46. Disponible en: https://www.sciencedirect.com/science/article/pii/S014067361831

  3. Group ASC, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018[acceso: 14/01/2019];379:1529-39. Disponible en: https://insights.ovid.com/vascularsurgery/ jvsu/2019/01/000/effects-aspirin-primary-prevention-persons/51/00005397

  4. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018[acceso: 14/01/2019];379:1509-18. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa1805819

  5. Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: Recommendation Statement. Ann Intern Med. 2016[acceso: 14/01/2019];164:836-45. Disponible en: https://annals.org/aim/fullarticle/2513179/aspirin-use-primary-prevention-cardiovasculardisease- colorectal-cancer-u-s

  6. Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019[acceso: 14/01/2019];40:607-17. Disponible en: https://academic.oup.com/eurheartj/article/40/7/607/5250614

  7. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017[acceso: 14/01/2019];38:804-10. Disponible en: https://academic.oup.com/eurheartj/article/38/11/804/2670140

  8. Castilla Guerra L, del Carmen Fernández Moreno M, de la Vega Sánchez JM, Jimenez DL. Evaluación del riesgo hemorrágico de la terapia antitrombótica en pacientes con ictus. Clínica e Investigación en Arteriosclerosis. 2019[acceso: 14/01/2018]. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0214916819300221

  9. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009[acceso: 14/01/2019];373:1849-60. Disponible en: https://europepmc.org/articles/pmc2715005

  10. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2018[acceso: 14/01/2019];00:1-33. Disponible en: https://academic.oup.com/eurheartj/advancearticleabstract/ doi/10.1093/eurheartj/ehy462/5079081

  11. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016[acceso: 14/01/2019];388:2532-61. Disponible en: https://www.sciencedirect.com/science/article/pii/S0140673616313575

  12. Hennekens CH, Schuttenberg N, Pfeffer MA. Prescription of Aspirin and Statins in Primary Prevention. Primary Care: Clinics in Office Practice. 2019[acceso: 14/01/2019];46(1):13-25. Disponible en: https://www.primarycare.theclinics.com/article/S0095-4543%2818%2930092-7/abstract

  13. Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, et al. Rationale, Design, and Baseline Characteristics of THEMIS: Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study. Clinical cardiology. 2019[acceso: 14/01/2019]. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/clc.23164

  14. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014[acceso: 14/01/2019];312:2510-20. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/1936801?

  15. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998[acceso: 14/01/2019];351:1755-62. Disponible en: https://www.sciencedirect.com/science/article/pii/S0140673698

  16. Bowman L, Mafham M, Stevens W, Haynes R, Aung T, Chen F, et al. ASCEND: A Study of Cardiovascular Events in Diabetes: characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. American heart Journal. 2018[acceso: 14/01/2019];198:135-44. Disponible en: https://www.sciencedirect.com/science/article/pii/S0002870317303927

  17. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018[acceso: 14/01/2019]. Disponible en: https://www.nejm.org/doi/full/10.1056/nejmoa1812792

  18. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. New England Journal of Medicine. 2018[acceso: 14/01/2019];379(16):1519-28. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa18

  19. Somuncu MU, Demir AR, Karakurt ST, Karakurt H, Karabag T. Desfecho Cardiovascular em Longo Prazo com Base na Capacidade de Resposta à Aspirina e ao Clopidogrel em Pacientes Jovens com Infarto do Miocárdio com Elevação do Segmento ST. Arq Bras Cardiol. 2019[acceso: 14/01/2019];112(2):138-46. Disponible en: http://publicacoes.cardiol.br/portal/abc/portugues/2019/v11202/pdf/11202006.pdf




2020     |     www.medigraphic.com